What is a key limitation of risk assessment tools like Tyrer-Cuzick in guiding breast cancer screening and chemoprevention?

What is a key limitation of risk assessment tools like Tyrer-Cuzick in guiding breast cancer screening and chemoprevention?

• A. They may not be fully applicable to all populations and may not fully account for genetic risk
• B. They provide exact predictions for every individual
• C. They are equally applicable across all populations with no limitations
• D. They replace the need for genetic testing

Answer: (A)

Risk models are built on data from specific populations, and the relationships they rely on may not hold the same way in every group. This means their predictions can be less accurate when applied to people who differ from the populations in which they were developed. A key limitation is therefore generalizability: calibration and discrimination can degrade in diverse populations, leading to under- or overestimation of an individual’s risk. In addition, while models like Tyrer-Cuzick may incorporate genetic information such as BRCA1/2 status, they do not fully capture the entire genetic contribution to risk, including polygenic risk scores and other rare high-penetrance variants. So the risk estimates can miss true high-risk individuals or misclassify others, depending on ancestry and genetic background. Because of these issues, risk assessment tools should be used as one part of the decision process for screening and chemoprevention, complemented by genetic testing results, family history, and individualized clinical context.

Risk models are built on data from specific populations, and the relationships they rely on may not hold the same way in every group. This means their predictions can be less accurate when applied to people who differ from the populations in which they were developed. A key limitation is therefore generalizability: calibration and discrimination can degrade in diverse populations, leading to under- or overestimation of an individual’s risk.

In addition, while models like Tyrer-Cuzick may incorporate genetic information such as BRCA1/2 status, they do not fully capture the entire genetic contribution to risk, including polygenic risk scores and other rare high-penetrance variants. So the risk estimates can miss true high-risk individuals or misclassify others, depending on ancestry and genetic background.

Because of these issues, risk assessment tools should be used as one part of the decision process for screening and chemoprevention, complemented by genetic testing results, family history, and individualized clinical context.